Evotec’s Just-Evotec Biologics has been selected by BARDA’s BioMaP Consortium for a program worth up to $10 million to optimize manufacturing of a monoclonal antibody cocktail targeting Ebola and Sudan virus infections.
Written by: Katherashala Dharan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Evotec SE announced that its Seattle-based subsidiary and contract development and manufacturing organization (CDMO), Just – Evotec Biologics, Inc., has been selected by the Biomedical Advanced Research and Development Authority (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to advance manufacturing optimization for a monoclonal antibody cocktail targeting filovirus disease, including Ebola virus (EBOV) and Sudan virus (SUDV).
The multi-year program, valued at up to $10 million if all options are exercised, is intended to strengthen U.S. national preparedness by supporting the development of cost-effective medical countermeasures against high-threat pathogens. The agreement includes a base period and two optional extension periods. While two FDA-approved therapies are currently available for Ebola virus disease, there are still no approved treatments for infections caused by the Sudan virus.
Under the collaboration, Just – Evotec Biologics will apply its technology platforms to carry out molecular optimization, cell line development, and manufacturing process development for two monoclonal antibodies. These antibodies were originally identified from survivors of the 2014 Ebola outbreak and are believed to represent protective immune responses against filovirus infection.
The company aims to transform these discoveries into scalable and cost-efficient manufacturing processes capable of supporting future therapeutic development and rapid deployment during public health emergencies.
Linda Zuckerman, PhD, EVP and Global Head of Biotherapeutics at Just – Evotec Biologics, said rapid and scalable manufacturing is essential during infectious disease outbreaks. She noted that the company’s technology-driven approach is designed to deliver high-yield, resilient production processes that enable faster response and deployment of biologic countermeasures.
The project is funded in whole or in part by the U.S. Department of Health and Human Services through the Administration for Strategic Preparedness and Response (ASPR) and BARDA.
Reference
Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses, 23 March 2026, Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses – Evotec
About the Writer
Katherashala Dharan Kumar, PharmD A dedicated Clinical Researcher with expertise in medical and scientific writing clinical trials, drug safety, and healthcare innovation. Actively contributes to research publications and clinical documentation focused on improving patient outcomes through evidence-based practices and ethical research standards. Believe that every complex data point has a human story waiting to be told. Focusing on providing actionable insights for clinical research